We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+23.07%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
AUM
$6.14B
AUM Growth
+$2.32B
Cap. Flow
+$1.46B
Cap. Flow %
23.76%
Top 10 Hldgs %
63.49%
Holding
77
New
9
Increased
16
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
TLN
Talen Energy Corp
TLN
+$1.6B
2
VST icon
Vistra
VST
+$67.7M
3
UAL icon
United Airlines
UAL
+$51.5M
4
THS
Treehouse Foods
THS
+$45.4M
5
DK icon
Delek US
DK
+$42.3M

Sector Composition

Rank Sector Weight
1 Utilities 39.48%
2 Healthcare 32.6%
3 Technology 5.2%
4 Industrials 5.14%
5 Energy 4.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$6.08B
$60.5M 0.99%
2,419,103
EXTR icon
27
Extreme Networks
EXTR
$3.21B
$59.1M 0.96%
3,931,913
-1,322,831
-25% -$18.7M
CAR icon
28
Avis
CAR
$4.95B
$58.9M 0.96%
672,406
-17,867
-3% -$1.61M
TAC icon
29
TransAlta
TAC
$3.99B
$58.3M 0.95%
5,622,961
+935,803
+20% +$7.78M
OFIX icon
30
Orthofix Medical
OFIX
$417M
$57.7M 0.94%
3,694,946
ADEA icon
31
Adeia
ADEA
$3.14B
$55.3M 0.9%
4,640,009
HRTX icon
32
Heron Therapeutics
HRTX
$62.7M
$53.2M 0.87%
26,713,503
SSYS icon
33
Stratasys
SSYS
$788M
$51.4M 0.84%
6,191,000
+222,297
+4% +$1.75M
ZYME icon
34
Zymeworks
ZYME
$1.84B
$49.2M 0.8%
3,917,331
COLL icon
35
Collegium Pharmaceutical
COLL
$919M
$48.3M 0.79%
1,250,000
-1,083,500
-46% -$38.6M
THS
36
DELISTED
Treehouse Foods
THS
$48M 0.78%
+1,143,664
New +$45.4M
XPER icon
37
Xperi
XPER
$321M
$38.3M 0.62%
4,143,744
TDOC icon
38
Teladoc Health
TDOC
$1.26B
$37.9M 0.62%
4,126,624
-501,908
-11% -$4.15M
DK icon
39
Delek US
DK
$4.15B
$37.5M 0.61%
+2,000,000
New +$42.3M
GDRX icon
40
GoodRx Holdings
GDRX
$1.26B
$32.5M 0.53%
4,680,028
+943,226
+25% +$7.4M
AIR icon
41
AAR Corp
AIR
$5.77B
$30.8M 0.5%
471,699
-103,301
-18% -$6.83M
FIP icon
42
FTAI Infrastructure
FIP
$547M
$29.5M 0.48%
3,150,352
-43,178
-1% -$401K
CNNE icon
43
Cannae Holdings
CNNE
$679M
$27.3M 0.44%
1,430,248
GLNG icon
44
CALL
Golar LNG
GLNG
$5.27B
$25.7M 0.42%
700,000
CSTM icon
45
Constellium
CSTM
$3.96B
$24.8M 0.4%
1,523,832
-2,139,063
-58% -$36.3M
SCPH
46
DELISTED
scPharmaceuticals
SCPH
$21.8M 0.35%
4,775,000
+1,250,000
+35% +$6.05M
ARDX icon
47
Ardelyx
ARDX
$1.01B
$21.1M 0.34%
3,060,191
+1,243,606
+68% +$7.34M
TRVI icon
48
Trevi Therapeutics
TRVI
$2.59B
$16.8M 0.27%
5,026,931
RSKD icon
49
Riskified
RSKD
$854M
$16M 0.26%
3,379,662
-793,974
-19% -$4.34M
EMBC icon
50
Embecta
EMBC
$287M
$15.3M 0.25%
+1,085,529
New +$15.8M

Similar funds

Rubric Capital Management (New York)'s Q3 2024 Portfolio in Review

As of Q3 2024, Rubric Capital Management (New York) held 77 positions worth $6.14B, up 61% from $3.81B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Rubric Capital Management (New York) deployed $1.46B of net new capital in Q3 2024, opening 9 new positions and adding to 16 existing holdings. Its largest new stake was Talen Energy Corp: 11,368,614 shares worth $2.03B.

By sector, the portfolio is most concentrated in Utilities at 39% of assets, up from 6.1% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Mr. Cooper, an estimated $42.8M trimmed.

  • Rubric Capital Management (New York)'s largest Q3 2024 buy was Talen Energy Corp: 11,368,614 shares worth $2.03B.
  • Rubric Capital Management (New York) added most to Vistra in Q3 2024, an estimated $67.7M increase.
  • Rubric Capital Management (New York)'s biggest Q3 2024 reduction was Mr. Cooper, cutting an estimated $42.8M.
  • Rubric Capital Management (New York) fully exited Jazz Pharmaceuticals in Q3 2024, selling an estimated $65.8M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 63% of its $6.14B portfolio in Q3 2024.
  • Rubric Capital Management (New York) opened 9 new positions and closed 12 in Q3 2024.
  • Rubric Capital Management (New York)'s portfolio value rose 61% quarter-over-quarter to $6.14B.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2024, filed 13 Nov 2024.